The Neuropathology Core is an essential part of the Alzheimer's Disease Core Center (ADCC). During life, the signs and symptoms of Alzheimer's disease (AD) are not sufficiently different from several other conditions, resulting in misdiagnosis, even at the most advanced centers, in about 25% of subjects. Examination of the brain after death by a certified Neuropathologist is therefore the only means by which a definite diagnosis can be attained, allowing all research results to be correctly interpreted. A second major role of the Neuropathology Core is to provide neuropathologically characterized brain tissue to basic scientists, both within the ADCC and outside it, enabling them to discover the underlying molecular mechanisms of disease and design appropriate therapeutic interventions. A detailed understanding of the genetic and molecular processes of disease pathogenesis, obtained by comparative study of diseased and non-diseased brain tissue, remains the major approach to finding such interventions. A third important goal of the Neuropathology Core is to help develop a collaborative synergy that will enhance the research productivity of the entire Center.
Our Specific Aims are as follows: 1)To provide precise neuropathoiogic diagnoses of patients that have been clinically studied by the Cinical Core. 2) To provide basic scientists with neuropathologically characterized brain tissue suitable for the elucidation of the molecular mechanisms of AD and related disorders, and especially to assist researchers in their studies of the earliest stages of Alzheimer's disease, with the goal of identifying therapeutic strategies that will prevent the disease or slow its progress. 3) To share neuropathological skills, expertise, knowledge and data with all ADCC investigators and the scientific community at large, facilitating a collaborative synergy that will enhance the research productivity of all.

Public Health Relevance

The Arizona Alzheimer's Disease Center's Neuropathology Core provides autopsy services, brain measurements and diagnoses, and brain and body samples from research participants in the Clinical Core who have died and donated their brains (and sometimes their bodies) to advance the scientific understanding, treatment and prevention of Alzheimer's disease. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-13
Application #
8501205
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$235,669
Indirect Cost
$96,029
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. J Am Geriatr Soc 66:671-678
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Liu, Li; Caselli, Richard J (2018) Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease. Alzheimers Dement (N Y) 4:602-608
Allen, Mariet; Wang, Xue; Burgess, Jeremy D et al. (2018) Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimers Dement 14:352-366
Zbesko, Jacob C; Nguyen, Thuy-Vi V; Yang, Tao et al. (2018) Glial scars are permeable to the neurotoxic environment of chronic stroke infarcts. Neurobiol Dis 112:63-78
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Subjective Cognitive Impairment and the Broad Autism Phenotype. Alzheimer Dis Assoc Disord 32:284-290
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Salloway, Stephen; Honigberg, Lee A; Cho, William et al. (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther 10:96

Showing the most recent 10 out of 794 publications